IMV Inc
TSX:IMV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
IMV Inc
TSX:IMV
|
CA |
Intrinsic Value
The intrinsic value of IMV Inc (IMV) under the Base Case is 2.88 CAD per share.
Compared with the current market price of 1.12 CAD, the stock appears
Undervalued by 61% .
The intrinsic value is calculated using the DCF method. Operating margin recovers from -20698% last year to -100% by 2029. Revenue grows about 12% a year over the next five years, about four times its five-year pace of 3%.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What IMV Does
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 97 full-time employees. The company went IPO on 2007-10-24. The firm is using its DPX delivery technology to achieve targeted immune activation.
- Headquarters
- Canada CA
- Employees
- 97
- IPO date
- Oct 24, 2007
Revenue & Expenses Breakdown
IMV Inc
Earnings Waterfall
IMV Inc
The intrinsic value for IMV Inc (IMV) under the Base Case is 2.88 CAD.
Compared with the current market price of 1.12 CAD, the stock appears Undervalued by 61% .
